Palvella Therapeutics Inc... (PVLA)
NASDAQ: PVLA
· Real-Time Price · USD
45.77
-0.33 (-0.72%)
At close: Aug 15, 2025, 1:07 PM
-0.72% (1D)
| Bid | 45.52 |
| Market Cap | 506.02M |
| Revenue (ttm) | 53K |
| Net Income (ttm) | -17.2M |
| EPS (ttm) | -2.53 |
| PE Ratio (ttm) | -18.09 |
| Forward PE | -13.51 |
| Analyst | Buy |
| Ask | 45.81 |
| Volume | 131,272 |
| Avg. Volume (20D) | 132,306 |
| Open | 47.12 |
| Previous Close | 46.10 |
| Day's Range | 44.24 - 47.97 |
| 52-Week Range | 11.17 - 47.97 |
| Beta | -0.01 |
About PVLA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PVLA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PVLA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-15.72%
Palvella Therapeutics shares are trading lower on ...
Unlock content with
Pro Subscription
6 months ago
+6.26%
Palvella Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $44.
1 week ago · https://thefly.com
Palvella Therapeutics initiated with an Outperform at Raymond JamesRaymond James initiated coverage of Palvella Therapeutics with an Outperform rating and $54 price target. The firm says the company is developing Qtorin rapamycin, a novel topical therapy designed to ...